Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H10O6S4 |
Molecular Weight | 282.379 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)CCSSCCS(O)(=O)=O
InChI
InChIKey=BYUKOOOZTSTOOH-UHFFFAOYSA-N
InChI=1S/C4H10O6S4/c5-13(6,7)3-1-11-12-2-4-14(8,9)10/h1-4H2,(H,5,6,7)(H,8,9,10)
Molecular Formula | C4H10O6S4 |
Molecular Weight | 282.379 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Dimesna is a prodrug of mesna (dimer of mesna). Dimesna is reduced to mesna in the kidneys. Dimesna does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in the renal tubular cell line LLC-PK1. Dimesna is a mucolytic agent used to alleviate toxic side effects of antitumor drugs. The organic acid transporter OAT4 on the luminal side of the proximal renal tubule facilitates the reabsorption of dimesna, and therefore its reduction to mesna, whereas the multidrug and toxin extrusion protein MATE1, the multidrug resistance protein MRP2, and P glycoprotein facilitate the efflux of mesna and/or dimesna back into the lumen; dimesna may also be excreted unchanged by MRP4. It has therefore been suggested that polymorphism of these renal transport proteins or transporter-mediated drug-drug interactions may reduce the efficacy of mesna and dimesna.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0046785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20807779 |
PubMed
Title | Date | PubMed |
---|---|---|
[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)]. | 1982 |
|
Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna. | 1983 Sep |
|
Efficient, chemoselective synthesis of immunomicelles using single-domain antibodies with a C-terminal thioester. | 2009 Jul 20 |
|
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. | 2010 Apr |
|
BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro. | 2010 Sep |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:08:41 GMT 2023
by
admin
on
Sat Dec 16 10:08:41 GMT 2023
|
Record UNII |
6Q2L2H0POF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6Q2L2H0POF
Created by
admin on Sat Dec 16 10:08:41 GMT 2023 , Edited by admin on Sat Dec 16 10:08:41 GMT 2023
|
PRIMARY | |||
|
DTXSID40196395
Created by
admin on Sat Dec 16 10:08:41 GMT 2023 , Edited by admin on Sat Dec 16 10:08:41 GMT 2023
|
PRIMARY | |||
|
65626
Created by
admin on Sat Dec 16 10:08:41 GMT 2023 , Edited by admin on Sat Dec 16 10:08:41 GMT 2023
|
PRIMARY | |||
|
1392829
Created by
admin on Sat Dec 16 10:08:41 GMT 2023 , Edited by admin on Sat Dec 16 10:08:41 GMT 2023
|
PRIMARY | |||
|
45127-11-5
Created by
admin on Sat Dec 16 10:08:41 GMT 2023 , Edited by admin on Sat Dec 16 10:08:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|